No non-compete clause in case of FDI in pharma deals

Tags: News
The Reserve Bank today said the non-compete clause will not be applicable in acquisition of existing pharma companies by foreign entities or investors except in certain special cases.

India allows 100 per cent FDI in pharma sector. While FDI is permitted through automatic route in case of greenfield investment or new venture, government approval is required in case of brownfield or existing companies.

"... It has now been decided with immediate effect that the existing policy would continue with the condition that ‘non-compete’ clause would not be allowed except in special circumstances with the approval of the Foreign Investment Promotion Board (FIPB)," RBI said in a notification.

Under a non-compete clause a party agrees not to enter into a similar trade in competition against another party as part of a deal.

The notification follows revision of the extant FDI policy for pharmaceutical sector by the government in January, 2014.

Last week, the central bank had allowed FDI in Limited Liability Partnership (LLP) formed and registered under the LLP Act, 2008 subject to the conditions.

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • India must follow China on its path to the future

    There are many theories, real and imagined, doing the rounds in the national and international media about Barack Obama’s overtures to ‘rebalance

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Will the adventurous UGC succeed?

The impact of the Modi government on the education sector ...

Zehra Naqvi

The urge to tell stories

One wants to tell a story, like Scheherzade, in order ...

Dharmendra Khandal

Don’t interfere with nature

Just before we celebrated the news of tiger numbers swelling, ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture